Vitamin D3, Folic Acid and Fexofenadine in Healthy Volunteers
NCT ID: NCT01856348
Last Updated: 2013-08-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
10 participants
INTERVENTIONAL
2013-05-31
2013-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* Trial with medicinal product
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1, 25 dihydroxyvitamin D3 intake
This is a single arm study.
Vitamin D
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Vitamin D
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. age 18 to 65 years at study entry
3. signed informed consent form
4. Body Mass Index \> 18 - \< 30 kg/m2
5. Participants must not have any other diseases (as assessed by the screening examination)
6. Participants must not take any concomitant medications except oral contraceptives in females
7. Normal blood count
Exclusion Criteria
2. Contemporaneous participation in any other study
3. Females only: pregnancy
4. Females only: breast-feeding
5. Clinically significant abnormal laboratory findings
6. Known or suspected present or past malignancies of any kind
7. Known or suspected active infections, serious infections in the preceding 3 months
8. Positive hepatitis B, hepatitis C and / or HIV 1/2 serology
9. Subjects known or suspected not to comply with the study regulations
10. Subjects employed at the participating departments of the University Hospital Zürich.
11. Known or suspected present or past diseases which may interfere with the study
12. smokers
13. alcohol or drug abuse
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Zurich
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gerd A Kullak-Ublick, Prof MD
Role: PRINCIPAL_INVESTIGATOR
University Hospital Zurich, Pharmacology and Toxicology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital Zurich, Dept. of Clinical Pharmacology and Toxicology
Zurich, Canton of Zurich, Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PHA-11-VID/FOL-01
Identifier Type: -
Identifier Source: org_study_id